The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 ...

The Axsome management team will provide an overview of SYMBRAVO and anticipated commercial plans. The presenters will be available to answer questions at the end of the presentation. To access the ...

A nurse has shared seven different ways you can differentiate between a headache and a migraine. There are several telltale ...

When Pamela Hobbs started to suffer memory loss and became clumsy, she thought it was the menopause, but it turned out to be ...